Antiretroviral treatments sometimes fail to work in people with HIV because of the virus' ability to "hide" in cells and then reemerge once therapy stops. Norway's Bionor tested anticancer drug romidepsin and a vaccine, Vacc-4x, in 17 HIV-positive patients in the hopes that the combo would force the virus out of hiding and then kill it.
It wasn't all that long ago that GlaxoSmithKline was considering a spinoff for its HIV drugs division, ViiV Healthcare. Now, though, the company is hanging on tight to that business--and building it up, too.
Bristol-Myers Squibb is getting out of HIV R&D, selling its pipeline to the GlaxoSmithKline-controlled ViiV Healthcare in a transaction worth as much as $3 billion.
China now counts more than half a million people with HIV/AIDS, and a new survey suggests that caseload reflects what could be a "hidden epidemic" in the Asia-Pacific region. Much of the recent increase is among adolescents.
A team at The Scripps Research Institute in La Jolla this week said they have identified four antibodies to target weaknesses in HIV, touting an "important advance" in HIV vaccine research that could assist in developing a vaccine.
Johnson & Johnson's Janssen announced that a Phase IIb study of a combination regimen of two investigational long-acting injectable HIV drugs found that the therapy performed similarly to a regimen consisting of three oral medications.
Gilead is facing mounting competition in the HIV space from players including GlaxoSmithKline's ViiV Healthcare. But now, it has a new combo product to tout in Genvoya, which won an FDA go-ahead Thursday.
Gilead Sciences won FDA approval for another combination tablet designed to keep HIV from replicating itself, a drug the company touts as a safer alternative to products already on the market.
A consortium of top-tier European research centers has snagged €23 million ($25 million) to take a HIV vaccine toward the clinic. The Imperial College London-led project is drawing on the scientific capabilities of 23 research centers in an attempt to move a HIV vaccine into Phase I within the next 5 years.
Roche is rolling out rapid tests for HIV, hepatitis C and hep C genotyping in Europe, continuing its molecular diagnostics winning streak a couple of weeks after scoring FDA approval for related tests and unveiling promising numbers for its testing business.